Apogee Therapeutics (APGE) announced positive interim Phase 1 results from its first-in-human trial of APG990. APG990 interim Phase 1 ...

Apogee's APG990 Phase 1 data show a 60-day half-life and strong tolerability, supporting long-interval dosing. A 2025 trial ...

Apogee Therapeutics, Inc. ( ($APGE) ) has released its Q4 earnings. Here is a breakdown of the information Apogee Therapeutics, Inc. presented to ...

Accelerated execution of Phase 2 APEX clinical trial for APG777, with Part A over-enrolled and Part B initiated ahead of schedule; topline Part A ...